Acute Coronary Syndrome - Pipeline Review, H2 2016

  • ID: 3960443
  • Report
  • 109 pages
  • Global Markets Direct
1 of 5

FEATURED COMPANIES

  • advanceCor GmbH
  • Bayer AG
  • CSL Limited
  • Japan Tobacco Inc.
  • MedImmune LLC
  • The Medicines Company
  • MORE
Acute Coronary Syndrome - Pipeline Review, H2 2016

Acute Coronary Syndrome - Pipeline Review, H2 2016, provides an overview of the Acute Coronary Syndrome (Cardiovascular) pipeline landscape.

Acute coronary syndrome is a term used for conditions brought on by sudden, reduced blood flow to the heart. Symptoms include chest pain, pain elsewhere in the body, such as the left upper arm or jaw, nausea, vomiting and shortness of breath. Risk factors include age, high blood pressure, high blood cholesterol, cigarette smoking and Type 2 diabetes. Treatment includes beta blockers, calcium channel blockers, cholesterol-lowering drugs and angiotensin-converting enzyme (ACE) inhibitors and angiotensin receptor blockers (ARBS).

Report Highlights:

Acute Coronary Syndrome - Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Acute Coronary Syndrome (Cardiovascular), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Acute Coronary Syndrome (Cardiovascular) pipeline guide also reviews of key players involved in therapeutic development for Acute Coronary Syndrome and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, Preclinical and Discovery stages are 1, 1, 6, 3, 9 and 1 respectively.Acute Coronary Syndrome.

Acute Coronary Syndrome (Cardiovascular) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:

- The pipeline guide provides a snapshot of the global therapeutic landscape of Acute Coronary Syndrome (Cardiovascular).
- The pipeline guide reviews pipeline therapeutics for Acute Coronary Syndrome (Cardiovascular) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Acute Coronary Syndrome (Cardiovascular) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Acute Coronary Syndrome (Cardiovascular) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Acute Coronary Syndrome (Cardiovascular)

Reasons to Buy:

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Acute Coronary Syndrome (Cardiovascular).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Acute Coronary Syndrome (Cardiovascular) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
READ MORE
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • advanceCor GmbH
  • Bayer AG
  • CSL Limited
  • Japan Tobacco Inc.
  • MedImmune LLC
  • The Medicines Company
  • MORE
Introduction

Acute Coronary Syndrome Overview

Therapeutics Development

Pipeline Products for Acute Coronary Syndrome - Overview

Acute Coronary Syndrome - Therapeutics under Development by Companies

Acute Coronary Syndrome - Pipeline Products Glance

Late Stage Products

Clinical Stage Products

Early Stage Products

Acute Coronary Syndrome - Products under Development by Companies

Acute Coronary Syndrome - Companies Involved in Therapeutics Development

advanceCor GmbH

Arena Pharmaceuticals, Inc.

Ascendia Pharmaceuticals LLC

Athera Biotechnologies AB

Bayer AG

Cardiome Pharma Corp.

Cerenis Therapeutics Holding SA

CSL Limited

Esperion Therapeutics, Inc.

HitGen LTD

Japan Tobacco Inc.

Lee's Pharmaceutical Holdings Limited

LipimetiX Development Inc

MedImmune LLC

Pfizer Inc.

The Medicines Company

Verseon Corporation

Acute Coronary Syndrome - Therapeutics Assessment

Assessment by Monotherapy Products

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Drug Profiles

4-WF - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

AEM-28 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

AEM-2802 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Biologics for Acute Coronary Syndrome - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

CER-001 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

clopidogrel bisulphate - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

COR-2 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

CSL-112 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

dalcetrapib - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

MDCO-216 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

MEDI-6012 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

PC-mAb - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

PF-06282999 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

PMC-6 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

PR-15 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

rivaroxaban - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Inhibit PCSK9 for Acute Coronary Syndrome and Atherosclerosis - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Inhibit Thrombin for Cardiovascular Diseases - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

temanogrel hydrochloride - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

tirofiban hydrochloride - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ZK-001 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Acute Coronary Syndrome - Dormant Projects

Acute Coronary Syndrome - Discontinued Products

Acute Coronary Syndrome - Product Development Milestones

Featured News & Press Releases

Sep 01, 2016: FDA Approves New AGGRASTAT Product Format

Aug 30, 2016: Completion of patient enrolment in the CARAT study - meeting the clinical schedule

Aug 23, 2016: DalCor Announces Opening of International Trial Sites for Its Dal-GenE Phase 3 Cardiovascular Outcomes Trial

Jul 18, 2016: DalCor Dalcetrapib Demonstrates Genotype-Dependent Effects on Cholesterol Efflux and Inflammation in Data Published by The Montreal Heart Institute in Circulation: Cardiovascular Genetics

Jul 07, 2016: Medicure Receives Response Letter from FDA on AGGRASTAT sNDA for New Indication

May 11, 2016: Medicure Files Application for New AGGRASTAT Product Format

Apr 26, 2016: DalCor Randomizes First Patient in the DalGenE Phase 3 Cardiovascular Outcomes Trial

Apr 25, 2016: Patent Term for Rivaroxaban Extended in US

Dec 14, 2015: The Medicines Company Announces Investigational Lipid Modulating Agent, MDCO-216, Phase 1 Data Published in European Heart Journal- Cardiovascular Pharmacotherapy

Nov 10, 2015: Cerenis Therapeutics: New Data for CER-001 Presented in Key Oral Session at American Heart Association Conference 2015

Sep 08, 2015: First patients enter phase II CARAT trial to assess reduction in atherosclerotic plaque using CER-001 in post Acute Coronary Syndrome (ACS) patients

Jul 23, 2015: Capstone Therapeutics Announces Patent Application for Novel, More Potent Chimeric Apo E Mimetic Peptides

Jun 08, 2015: DalCor Pharma licenses a late-stage investigational cardiovascular drug following major scientific discovery

May 11, 2015: Xarelto Bleeding Lawsuit Judge Orders the Selection of Cases for Discovery, Reports Xarelto Lawsuit Funding Firm, Fair Rate Funding

List of Tables

Number of Products under Development for Acute Coronary Syndrome, H2 2016

Number of Products under Development by Companies, H2 2016

Comparative Analysis by Late Stage Development, H2 2016

Comparative Analysis by Clinical Stage Development, H2 2016

Comparative Analysis by Early Stage Development, H2 2016

Products under Development by Companies, H2 2016

Acute Coronary Syndrome - Pipeline by advanceCor GmbH, H2 2016

Acute Coronary Syndrome - Pipeline by Arena Pharmaceuticals, Inc., H2 2016

Acute Coronary Syndrome - Pipeline by Ascendia Pharmaceuticals LLC, H2 2016

Acute Coronary Syndrome - Pipeline by Athera Biotechnologies AB, H2 2016

Acute Coronary Syndrome - Pipeline by Bayer AG, H2 2016

Acute Coronary Syndrome - Pipeline by Cardiome Pharma Corp., H2 2016

Acute Coronary Syndrome - Pipeline by Cerenis Therapeutics Holding SA, H2 2016

Acute Coronary Syndrome - Pipeline by CSL Limited, H2 2016

Acute Coronary Syndrome - Pipeline by Esperion Therapeutics, Inc., H2 2016

Acute Coronary Syndrome - Pipeline by HitGen LTD, H2 2016

Acute Coronary Syndrome - Pipeline by Japan Tobacco Inc., H2 2016

Acute Coronary Syndrome - Pipeline by Lee's Pharmaceutical Holdings Limited, H2 2016

Acute Coronary Syndrome - Pipeline by LipimetiX Development Inc, H2 2016

Acute Coronary Syndrome - Pipeline by MedImmune LLC, H2 2016

Acute Coronary Syndrome - Pipeline by Pfizer Inc., H2 2016

Acute Coronary Syndrome - Pipeline by The Medicines Company, H2 2016

Acute Coronary Syndrome - Pipeline by Verseon Corporation, H2 2016

Assessment by Monotherapy Products, H2 2016

Number of Products by Stage and Target, H2 2016

Number of Products by Stage and Mechanism of Action, H2 2016

Number of Products by Stage and Route of Administration, H2 2016

Number of Products by Stage and Molecule Type, H2 2016

Acute Coronary Syndrome - Dormant Projects, H2 2016

Acute Coronary Syndrome - Dormant Projects (Contd..1), H2 2016

Acute Coronary Syndrome - Discontinued Products, H2 2016

Acute Coronary Syndrome - Discontinued Products (Contd..1), H2 2016

List of Figures

Number of Products under Development for Acute Coronary Syndrome, H2 2016

Number of Products under Development by Companies, H2 2016

Comparative Analysis by Late Stage Development, H2 2016

Comparative Analysis by Clinical Stage Development, H2 2016

Comparative Analysis by Early Stage Products, H2 2016

Assessment by Monotherapy Products, H2 2016

Number of Products by Top 10 Targets, H2 2016

Number of Products by Stage and Top 10 Targets, H2 2016

Number of Products by Top 10 Mechanism of Actions, H2 2016

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016

Number of Products by Routes of Administration, H2 2016

Number of Products by Stage and Routes of Administration, H2 2016

Number of Products by Molecule Types, H2 2016

Number of Products by Stage and Molecule Types, H2 2016
Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5
- advanceCor GmbH
- Arena Pharmaceuticals, Inc.
- Ascendia Pharmaceuticals LLC
- Athera Biotechnologies AB
- Bayer AG
- Cardiome Pharma Corp.
- Cerenis Therapeutics Holding SA
- CSL Limited
- Esperion Therapeutics, Inc.
- HitGen LTD
- Japan Tobacco Inc.
- Lee's Pharmaceutical Holdings Limited
- LipimetiX Development Inc
- MedImmune LLC
- Pfizer Inc.
- The Medicines Company
- Verseon Corporation
Note: Product cover images may vary from those shown
5 of 5
Note: Product cover images may vary from those shown
Adroll
adroll